Jorge Hernando - Publications

Correction: A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217).

Journal: BMC cancer

Published: June 13, 2026

Prognostic modeling of overall survival in metastatic pancreatic cancer: an inflammation-based tool validated in PANTHEIA-SEOM cohort.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: June 09, 2026

Review of Haematological Toxicities in Well-Differentiated Neuroendocrine Tumours: A Case Report and Comprehensive Review of the Literature.

Journal: Journal of clinical medicine

Published: May 11, 2026

Real-World outcomes and prognostic factors in anaplastic thyroid cancer: Evidence from the REGETNE-Thyroid cohort.

Journal: The oncologist

Published: February 27, 2026

Real-world outcomes and prognostic factors in anaplastic thyroid cancer: evidence from the REGETNE-Thyroid cohort.

Journal: The oncologist

Published: February 27, 2026

Axitinib and Long-Acting Octreotide in Advanced Extrapancreatic Neuroendocrine Tumors: A Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trial (AXINET, GETNE 1107).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: February 20, 2026

Case Report: Lorlatinib for the treatment of ALK-rearranged poorly differentiated thyroid carcinoma after progression to prior ALK-specific tyrosine-kinase inhibitor.

Journal: Frontiers in oncology

Published: February 02, 2026

Can clinicians predict individual patient outcomes in neuroendocrine tumors treated with [177Lu]Lu-DOTATATE?

Journal: The oncologist

Published: January 19, 2026

Inferior Vena Cava Stenosis Mimicking Right Heart Failure in Carcinoid Heart Disease.

Journal: JACC. Case reports

Published: January 19, 2026

A prediction tool for malnutrition and sarcopenia in patients with gastroenteropancreatic neuroendocrine neoplasms: results from NUTRIGETNE (GETNE-S2109) study.

Journal: Frontiers in nutrition

Published: January 19, 2026

Can clinicians predict individual patient outcomes in neuroendocrine tumors treated with [177Lu]Lu-DOTATATE?

Journal: The oncologist

Published: January 19, 2026

[177Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Journal: Lancet (London, England)

Published: December 04, 2025